- 专利标题： Heterocyclic amide compound
-
申请号： US16332993申请日： 2017-09-14
-
公开(公告)号： US10800754B2公开(公告)日： 2020-10-13
- 发明人: Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Masato Yoshida , Shinichi Imamura
- 申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 申请人地址： JP Osaka
- 专利权人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 当前专利权人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 当前专利权人地址： JP Osaka
- 代理机构： Wenderoth, Lind & Ponack, L.L.P.
- 优先权： com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6baf7514
- 国际申请： PCT/JP2017/033214 WO 20170914
- 国际公布： WO2018/052066 WO 20180322
- 主分类号： C07D401/04
- IPC分类号： C07D401/04 ; C07D401/14 ; C07D407/14 ; C07D409/14 ; C07D417/14 ; A61P35/00
摘要：
Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
公开/授权文献
- US20190359587A1 HETEROCYCLIC AMIDE COMPOUND 公开/授权日：2019-11-28
信息查询
